Efficacy of Subgingivally Delivered Satranidazole in the Treatment of Type 2 Diabetes Subjects with Chronic Periodontitis: A Randomized Controlled Clinical Trial.

Journal of the International Academy of Periodontology Pub Date : 2015-04-01

N Priyanka, Nitish Kalra, Shahab Saquib, Shahabe Saquib, Nikhil Malgaonkar, Malgaonkar Nikhil, Bassel Tarakji, Jadhav Varsha, Davangere Umashree, A R Pradeep

{"title":"Efficacy of Subgingivally Delivered Satranidazole in the Treatment of Type 2 Diabetes Subjects with Chronic Periodontitis: A Randomized Controlled Clinical Trial.","authors":"N Priyanka, Nitish Kalra, Shahab Saquib, Shahabe Saquib, Nikhil Malgaonkar, Malgaonkar Nikhil, Bassel Tarakji, Jadhav Varsha, Davangere Umashree, A R Pradeep","doi":"","DOIUrl":null,"url":null,"abstract":"Background: The present clinical trial was designed to investigate the effectiveness of subgingivally delivered satranidazole (SZ) gel as an adjunct to scaling and root planing (SRP) in the treatment of chronic periodontitis.Methods: Sixty-four subjects with probing depth (PD) ≥ 5 mm and who were diagnosed with type 2 diabetes were selected. Thirty-two subjects each were randomly assigned to SRP + placebo (Group 1) and SRP + SZ (Group 2). The clinical outcomes evaluated were plaque index (PI), gingival index (GI), clinical attachment level (CAL) and PD at baseline, 1 month, 3-months and 6 months.Results: At 6 months, Group 2 had greater mean reduction (4.73 mm) in PD as compared to Group 1 (2.09 mm; p < 0.05) and also a greater mean CAL gain (3.92 mm versus 1.64 mm; p < 0.05).Conclusion: The use of 3% SZ gel, when used as an adjunct to non-surgical periodontal therapy in subjects with periodontitis, achieves significantly better clinical results than initial periodontal treatment alone.","PeriodicalId":17281,"journal":{"name":"Journal of the International Academy of Periodontology","volume":"17 2","pages":"42-8"},"PeriodicalIF":0.0000,"publicationDate":"2015-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the International Academy of Periodontology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The present clinical trial was designed to investigate the effectiveness of subgingivally delivered satranidazole (SZ) gel as an adjunct to scaling and root planing (SRP) in the treatment of chronic periodontitis.

Methods: Sixty-four subjects with probing depth (PD) ≥ 5 mm and who were diagnosed with type 2 diabetes were selected. Thirty-two subjects each were randomly assigned to SRP + placebo (Group 1) and SRP + SZ (Group 2). The clinical outcomes evaluated were plaque index (PI), gingival index (GI), clinical attachment level (CAL) and PD at baseline, 1 month, 3-months and 6 months.

Results: At 6 months, Group 2 had greater mean reduction (4.73 mm) in PD as compared to Group 1 (2.09 mm; p < 0.05) and also a greater mean CAL gain (3.92 mm versus 1.64 mm; p < 0.05).

Conclusion: The use of 3% SZ gel, when used as an adjunct to non-surgical periodontal therapy in subjects with periodontitis, achieves significantly better clinical results than initial periodontal treatment alone.

微信好友朋友圈 QQ好友复制链接

本刊更多论文

沙硝唑龈下给药治疗2型糖尿病合并慢性牙周炎的疗效:一项随机对照临床试验。

背景:本临床试验旨在研究经龈下给药沙硝唑(SZ)凝胶作为刮治和牙根规划(SRP)辅助治疗慢性牙周炎的有效性。方法:选择诊断为2型糖尿病的探查深度(PD)≥5 mm的受试者64例。将32名受试者随机分为SRP +安慰剂组(1组)和SRP + SZ组(2组)。临床结果评估为基线、1个月、3个月和6个月时的斑块指数(PI)、牙龈指数(GI)、临床依恋水平(CAL)和PD。结果:6个月时，第2组PD平均缩小(4.73 mm)比第1组(2.09 mm;p < 0.05)，平均CAL增重也更高(3.92 mm vs 1.64 mm;P < 0.05)。结论:3% SZ凝胶作为牙周炎患者非手术牙周治疗的辅助治疗，其临床效果明显优于单纯的初始牙周治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of the International Academy of Periodontology

自引率

0.00%

发文量